At a glance
ClinicalIndex Comparison RecordN/ACompleted· 847 enrolled
Drug / intervention
Relestat Ophthalmic Solution 0.05%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea
In Brief
An observational study evaluating Relestat Ophthalmic Solution 0.05% for Conjunctivitis, Allergic. Completed, enrolled 847 participants across 1 site.
Detailed Summary
This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of Relestat Ophthalmic Solution 0.05% in patients with allergic conjunctivitis who are treated with Relestat as standard of care in clinical practice.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsConjunctivitis, Allergic
CountriesSouth Korea
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2009
Primary CompletionSep 2012
First PostedNov 2013
TodayJul 2026
First PostedNov 19, 2013
Enrollment StartJan 1, 2009
Primary CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 12.6 years ago
Interventions
Relestat Ophthalmic Solution 0.05%drug
Relestat Ophthalmic Solution 0.05% prescribed as local standard of care in clinical practice.